Stockscreener 앱 받기
5.43
1.69%
0.09
시간 외 거래:
5.45
0.02
+0.37%
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - stocktwits.com
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - stocktwits.com
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
DC’s Vanda Pharmaceuticals Wins EU Orphan Status for Its Rare Skin Disease Drug - biobuzz.io
Four September conferences are planned for Vanda Pharmaceuticals. Two presentations may be accessed live. - Stock Titan
Vanda Pharmaceuticals Inc. (VNDA) Peer Comparison – Compare with Others - Value Research
Convert Vanda Pharmaceuticals Inc. (VNDA) to Canadian Dollar (CAD) - Crypto.com
Millennium Management Expands Vanda Pharmaceuticals Stake Amid D - GuruFocus
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - webull.com
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. - Sahm
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA) - Stock Titan
DC Circuit Partially Rejects Vanda’s Fight of Generic Sleep Drug - Bloomberg Law News
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
Vanda Pharmaceuticals Inc (VNDA) (Q2 2026) Earnings Call Highlig - GuruFocus
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating - marketscreener.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 - Investing.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 By Investing.com - Investing.com Canada
VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Pharmaceuticals Inc (VM4.DU) insider ownership and holdings - Yahoo Finance Australia
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda Posts Wider Q2 Loss as Spending Surges; Revenue Dips 4% on Hetlioz Decline - finance.biggo.com
Vanda Pharmaceuticals Inc. Quarterly Earnings Report - Stock Titan
Vanda Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Arrowstreet Capital Limited Partnership Buys New Position in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Vanda misses Q2 2026 estimates as losses widen - Investing.com
Is Vanda Pharmaceuticals (VNDA) Facing Growth Challenges After Q - GuruFocus
Vanda Pharmaceuticals (NASDAQ:VNDA) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPS - MarketBeat
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Inc. Reiterates Revenue Guidance for the Full-Year 2026 - marketscreener.com
Vanda Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
VANDA PHARMACEUTICALS ($VNDA) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results - AOL.com
Vanda Pharmaceuticals Q2 loss widens on lower sales, higher costs - TradingView
BRIEF-Vanda Pharmaceuticals Q2 EPS USD -1.04 - TradingView
Vanda Pharmaceuticals Inc expected to post a loss of 59 cents a shareEarnings Preview - TradingView
Vanda investors can hear its Q2 update Aug. 5 at 4:30 p.m. - Stock Titan
Vanda Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
$5.23 | Vanda Pharmaceuticals Inc. Common Stock (VNDA) Stock Price Today - Binance
Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.86%
0.31%
자본화:
|
볼륨(24시간):